Phase Genomics Revenue and Competitors
Estimated Revenue & Valuation
- Phase Genomics's estimated annual revenue is currently $3.1M per year.
- Phase Genomics's estimated revenue per employee is $155,000
- Phase Genomics's total funding is $6M.
Employee Data
- Phase Genomics has 20 Employees.
- Phase Genomics grew their employee count by -51% last year.
Phase Genomics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder & CEO | Reveal Email/Phone |
2 | COO | Reveal Email/Phone |
3 | VP Business Development | Reveal Email/Phone |
4 | VP Research and Development | Reveal Email/Phone |
5 | Product Marketing Manager | Reveal Email/Phone |
6 | Senior Product Manager | Reveal Email/Phone |
7 | Software Engineer II | Reveal Email/Phone |
8 | Research Scientist | Reveal Email/Phone |
9 | Research Scientist | Reveal Email/Phone |
10 | Senior Bioinformatics Lead | Reveal Email/Phone |
Phase Genomics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $258.5M | 866 | -19% | $1.1B | $2.4B |
What Is Phase Genomics?
Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples as well as industry-leading genome and metagenome assembly and analysis software. Founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs, the company's mission is to empower scientists with state-of-the-art genomic tools that will accelerate breakthrough discoveries. The company serves academic and commercial researchers in diverse fields and industries.
keywords:N/A
$6M
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
-51%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Phase Genomics News
This table compares Denali Therapeutics and Quantum Genomics Société ... The company also develops DNL310 that is in Phase I/II clinical...
Genomic Consortium Diversifies Data, Explores Genomics of Body ... the globe and we look forward to seeing this through to the next phase.
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2M | 20 | N/A | N/A |
#2 | $2M | 20 | -17% | $95.3M |
#3 | $3.5M | 20 | -9% | N/A |
#4 | $3.4M | 20 | -5% | N/A |
#5 | $3.1M | 20 | -9% | N/A |